S&P TSX Capped Composite...

US Dollar vs CAD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

ATHE Alterity Therapeutics Limited

2.1899

0.0949 (4.53%)

Last Updated: 10:02:45

Delayed by 15 minutes

Alterity surges on funding win for ATH434 development

To read the full story on Seeking Alpha, click here.

Alterity Therapeutics (NASDAQ:ATHE)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Alterity Therapeutics Charts.

Alterity Therapeutics (NASDAQ:ATHE)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Alterity Therapeutics Charts.

Alterity Therapeutics Limited News

Appendix 4C – Q3 FY24 Quarterly Cash Flow Report
Tuesday 30 April 2024 (1 day ago) • GlobeNewswire Inc.

Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia
Monday 29 April 2024 (2 days ago) • GlobeNewswire Inc.

Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
Wednesday 17 April 2024 (2 weeks ago) • GlobeNewswire Inc.

Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024
Wednesday 10 April 2024 (3 weeks ago) • GlobeNewswire Inc.

Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund
Tuesday 26 March 2024 (1 month ago) • GlobeNewswire Inc.

Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting
Tuesday 20 February 2024 (2 months ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Thursday 15 February 2024 (2 months ago) • Edgar (US Regulatory)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Thursday 15 February 2024 (2 months ago) • Edgar (US Regulatory)

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review
Tuesday 6 February 2024 (3 months ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Wednesday 31 January 2024 (3 months ago) • Edgar (US Regulatory)

Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week
Monday 29 January 2024 (3 months ago) • GlobeNewswire Inc.

Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones
Monday 22 January 2024 (3 months ago) • GlobeNewswire Inc.

More Alterity Therapeutics Limited News Articles

Global Developments (PK)

Yuenglings Ice Cream (PK)

FBEC Worldwide (PK)

CBD of Denver (PK)

Virexit Technologies (PK)

Elite Pharmaceuticals (QB)

Tonner One World (PK)

Branded Legacy (PK)

Impact Fusion (PK)

BlueFire Equipment (PK)

Canopus Biopharma (PK)

International Star (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions